German science and technology company Merck KGaA (MRK: DE) reported an 18.2% increase in net sales to 3.8 billion euros ($4.2 billion) in its second quarter 2016 results.
Earnings before interest, taxes, amortization and depreciation (EBITDA) pre-exceptionals, also rose sharply, by 29% to 1.2 billion euros, driven by the good operating performance of healthcare and life sciences as well as the Sigma-Aldrich acquisition. This was slightly higher than analyst estimates of 1.1 billion euros.
Earnings per share (EPS) pre-exceptionals also rose in the second quarter by 19.2% to 1.55 euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze